Representative Robert Bresnahan Jr. recently waved goodbye to his Regeneron Pharmaceuticals shares, sparking curiosity over ...

Real-time index price for TSX Composite High Dividend Index (TXEI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Regeneron Pharmaceuticals Up Nearly 7%, On Pace For Largest Percent Increase Since September 2022 — Data Talk Regeneron Pharmaceuticals, Inc. (REGN) is currently at $568.11, up $40.33 or 7.64% --On ...

In a longer-term context, Regeneron's total shareholder return, including dividends, was a decline of 8.37% over the past five years. This performance trails the past year's market return of 8% and ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...

Regeneron Pharmaceuticals currently returns an annual dividend yield of 0.2%. The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a ...